

Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Tom Kouroukis

Name of drug and indication under review: brentuximab/HL post ASCT consolidation

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Sec 1.	Have y	Payment Received you received any payments over the pre- ization that may have direct or indirect i		
	If no, p	lease go to Section B.		
2.	What f	form of payment did you receive? (Chec	k all tha	at apply.)
		Advisory role (e.g., advisory boards, HTA submission advice) Conference attendance		Program or Operating Funding (e.g., website) Research/educational grants
		Royalties		Travel grants
		Gifts		Sponsorship of Events
		Honoraria		
		Other, please specify: Click here to enter	lext.	
3.		e provide the names of companies and o box below.	organiz	ations and the amounts of the payments

Click here to enter text.



Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

None-

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

None

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

Name:

Click here to enter text. MAY 18, 2017

Click here to enter text. C. TOM KOUROUKIS, MD

Click here to enter text.

Click here to enter text.

Signature: Click here to enter text.



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Jordan Herst

Name of drug and indication under review: brentuximab/HL post ASCT consolidation

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- · affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

	Have y	: Payment Received you received any payments over the pre ization that may/have direct or indirect		
	☐ Yes	S ∆VNo		
	If no, p	elease go to Section B.		
2.	2. What form of payment did you receive? (Check all that apply.)			
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)
		Conference attendance		Research/educational grants
		Royalties		Travel grants
		Gifts		Sponsorship of Events
		Honoraria		
		Other, please specify: Click here to enter	text	
3.		e provide the names of companies and box below.	organiz	zations and the amounts of the payments

Click here to enter text



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

NO

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Toedon A Herof

Date:

June 16, 2017

Name:

Jordan Herst

Signature:



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Click here to enter te	Xŧ.				
Name of drug and indication under review: Click here to enter text. brentuximab/HL post ASCT consolidation					
Conflict of Interest Declarations To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.					
Examples of conflicts of interest include, but are not financial support from the pharmaceutical industry honoraria, gifts, and salary; affiliations or personal or commercial relationships.	y or oth	er entities e.g., educational or research grants,			
Section A: Payment Received 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? □ Yes No					
If no, please go to Section B.					
2. What form of payment did you receive? (Che	ck all th	nat apply.)			
 □ Advisory role (e.g., advisory boards, HTA submission advice) □ Conference attendance □ Royalties □ Gifts □ Honoraria □ Other, please specify: Click here to enter 	c text.	Program or Operating Funding (e.g., website) Research/educational grants Travel grants Sponsorship of Events			
Please provide the names of companies and in the box below. Click here to enter text.	organia	zations and the amounts of the payments			



Before completing this template, be sure to register with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

NO

Amendment(July 6, 2017): personal holding of Novartis stocks

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

Click here to enter text.

Name:

Click here to enter text.

Signature:

Click here to enter text.

Amended: July 6, 2017

anet Mac Eachern



Before completing this template, be sure to register with the pCODR program.

Please visit https://www.cadth.ca/pcodr/r

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Anca Prica

Name of drug and indication under review: brentuximab/HL post ASCT consolidation

Conflict of Interest Declarations

Janssen, Lundbeck

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:
 financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;

· affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Sec	ction A	: Payment Received		
1.		you received any payments over the pre ization that may have direct or indirect ☐ No		
	If no, p	please go to Section B.		
2.	. What form of payment did you receive? (Check all that apply.)			
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)
		Conference attendance		Research/educational grants
		Royalties		Travel grants
		Gifts		Sponsorship of Events
	\boxtimes	Honoraria		
		Other, please specify:		
3.		e provide the names of companies and box below.	organiz	zations and the amounts of the payments



Before completing this template, be sure to register with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

None

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

None

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

July 20, 2017

Name:

A--- D-i--

Signature:

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: John Kuruvilla

Name of drug and indication under review: Brentuximab maintenance post-ASCT

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

		-		
1.	 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? 			
	X	Yes No		
	lf n	o, please go to Section	В	
2.	2. What form of payment did you receive? (Check all that apply.)			
	X	Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)
		Conference attendance	Χ	Research/educational grants
		Royalties		Travel grants
		Gifts		Sponsorship of Events
		Honoraria		Other, please specify:

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

3.	Please provide the names of companies and organizations and the amounts of the payments in the box below.						
	Seattle Genetics - approximately \$ over 5 years Merck - approximately \$ over 3 years BMS - approximately \$ over 3 years						
Sec	tion B: Holdings or Other Interests						
mu	ve you received or is it in possession of stocks or options of more than \$10,000 (excluding tual funds) for organizations that may have a direct or indirect interest in the drug under iew? If yes, please list in the table below.						
no	one						
Sec	tion C: Affiliations, personal or commercial relationships						
mai asse	you have personal or commercial relationships either with a drug or health technology nufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and ociated corporations) or other interest groups? If yes, please provide the names of the apanies and organizations and outline the nature of these relationships in the table below.						
no	ne						
I he a Pa	reby certify that I have disclosed all relevant information with respect to any matter involving arty that may place me in a real, potential or perceived conflict of interest situation.						
Date	e: 23-Aug-2017 Name: John Kuruvilla Signature: 16 Manual						